The main clinical manifestation of myasthenia gravis is the fatigue and weakness of local or generalized transverse muscles during activity, and the eye muscles are the most vulnerable muscle group in myasthenia gravis. A few patients with myasthenia gravis may have a family history (familial inherited myasthenia gravis). Some patients can have a long period of remission, but patients with this disease often relapse or worsen due to a variety of factors such as mental trauma, various systemic infections, overexertion, endocrine disorders, immune dysfunction, women’s menstrual periods, use of anesthesia, analgesic and sedative drugs, childbirth, surgery, and certain antibiotics (such as mucomycin, streptomycin, kanamycin and other drugs). Myasthenia gravis is a disease with a more aggressive clinical progression and can cause serious consequences if not treated actively. There are many treatment options, including cholinesterase inhibitors, immunosuppressants, thymectomy, intravenous high-dose immunoglobulin (IVIg), and blood purification. Thymectomy is considered by many physicians to be the preferred treatment option for myasthenia gravis.